You established for Clean Hold Time (CHT) and Dirty Hold Time Study (DHT) for the following shared equipment (non-dedicated) that is used to manufacture : which was not based on the worst-case molecules.
Inspection Record
Shilpa Medicare Limited — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Written records are not always made of investigations into unexplained discrepancies.
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Production records do not contain complete information relating to the production and control of each batch.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Apotek Production & Laboratorier AB2026-01-29 · US FDASimilar to finding 4 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
- Greer Laboratories, Inc.2024-12-18 · US FDASimilar to finding 4 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
- Fresenius Kabi USA, LLC2026-05-14 · US FDASimilar to finding 4 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
- Gland Pharma Limited2025-02-25 · US FDASimilar to finding 4 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
- Microvascular Tissue, Inc2025-04-08 · US FDASimilar to finding 4 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
A record as of the US FDA document published on 2026-10-22. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.